[go: up one dir, main page]

MX2023013099A - Preparacion que contiene un compuesto de peptido ciclico y metodo para su produccion. - Google Patents

Preparacion que contiene un compuesto de peptido ciclico y metodo para su produccion.

Info

Publication number
MX2023013099A
MX2023013099A MX2023013099A MX2023013099A MX2023013099A MX 2023013099 A MX2023013099 A MX 2023013099A MX 2023013099 A MX2023013099 A MX 2023013099A MX 2023013099 A MX2023013099 A MX 2023013099A MX 2023013099 A MX2023013099 A MX 2023013099A
Authority
MX
Mexico
Prior art keywords
preparation containing
cyclic peptide
containing cyclic
peptide compound
producing same
Prior art date
Application number
MX2023013099A
Other languages
English (en)
Inventor
Takamitsu Ueto
Yukari Kuboki
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2023013099A publication Critical patent/MX2023013099A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con una composición que contiene un compuesto representado por la Fórmula (1): (ver Fórmula) (1) o una sal del mismo o un solvato del mismo; un aditivo líquido; y opcionalmente un componente aceitoso.
MX2023013099A 2021-05-07 2022-05-06 Preparacion que contiene un compuesto de peptido ciclico y metodo para su produccion. MX2023013099A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021079015 2021-05-07
PCT/JP2022/019540 WO2022234850A1 (ja) 2021-05-07 2022-05-06 環状ペプチド化合物を含む製剤及びその製造方法

Publications (1)

Publication Number Publication Date
MX2023013099A true MX2023013099A (es) 2023-11-17

Family

ID=83932759

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013099A MX2023013099A (es) 2021-05-07 2022-05-06 Preparacion que contiene un compuesto de peptido ciclico y metodo para su produccion.

Country Status (12)

Country Link
US (1) US20240366711A1 (es)
EP (1) EP4299069A4 (es)
JP (2) JP7181442B1 (es)
KR (2) KR102582225B1 (es)
CN (1) CN117241817A (es)
AU (1) AU2022270498A1 (es)
BR (1) BR112023019622A2 (es)
CA (1) CA3219090A1 (es)
IL (1) IL306018A (es)
MX (1) MX2023013099A (es)
TW (1) TW202308679A (es)
WO (1) WO2022234850A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9409952B2 (en) 2011-12-28 2016-08-09 Chugai Seiyaku Kabushiki Kaisha Peptide-compound cyclization method
CA3159931A1 (en) 2019-11-07 2021-05-14 Chugai Seiyaku Kabushiki Kaisha Cyclic peptide compound having kras inhibitory action
AR125800A1 (es) 2021-05-07 2023-08-16 Chugai Pharmaceutical Co Ltd Métodos para producir compuestos cíclicos que comprendan residuos de aminoácidos sustituidos con n
CA3256645A1 (en) 2022-05-06 2025-04-23 Chugai Seiyaku Kabushiki Kaisha CYCLIC COMPOUND HAVING A SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS
CN120051479A (zh) * 2022-10-20 2025-05-27 中外制药株式会社 用于生产环肽晶体的方法
TW202506706A (zh) * 2023-04-20 2025-02-16 日商中外製藥股份有限公司 環狀胜肽化合物的製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012112319A1 (en) * 2011-02-04 2012-08-23 Aegis Therapeutics, Llc Orally bioavailable peptide drug compositions and methods thereof
EP2681235B1 (en) 2011-03-04 2016-05-04 New York University Hydrogen bond surrogate macrocycles as modulators of ras
US9409952B2 (en) * 2011-12-28 2016-08-09 Chugai Seiyaku Kabushiki Kaisha Peptide-compound cyclization method
EA036036B1 (ru) 2014-11-07 2020-09-16 Сигмойд Фарма Лимитед Композиции, содержащие циклоспорин
US10954287B2 (en) 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
US10808010B2 (en) 2016-08-11 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide inhibitors of phosphoglycerate mutase and methods of use
EP3636807A4 (en) 2017-06-09 2021-07-28 Chugai Seiyaku Kabushiki Kaisha CYCLIC PEPTIDE COMPOUND WITH HIGH MEMBRANE PERMEABILITY AND LIBRARY WITH IT
US20230096766A1 (en) 2018-12-12 2023-03-30 Chugai Seiyaku Kabushiki Kaisha Amino acid having functional group capable of intermolecular hydrogen bonding, peptide compound containing same and method for production thereof
CA3159931A1 (en) * 2019-11-07 2021-05-14 Chugai Seiyaku Kabushiki Kaisha Cyclic peptide compound having kras inhibitory action
AR125800A1 (es) * 2021-05-07 2023-08-16 Chugai Pharmaceutical Co Ltd Métodos para producir compuestos cíclicos que comprendan residuos de aminoácidos sustituidos con n

Also Published As

Publication number Publication date
KR102582225B1 (ko) 2023-09-22
JP2023015334A (ja) 2023-01-31
JPWO2022234850A1 (es) 2022-11-10
US20240366711A1 (en) 2024-11-07
WO2022234850A1 (ja) 2022-11-10
CA3219090A1 (en) 2022-11-10
EP4299069A1 (en) 2024-01-03
CN117241817A (zh) 2023-12-15
IL306018A (en) 2023-11-01
AU2022270498A1 (en) 2023-10-05
EP4299069A4 (en) 2025-03-05
KR20230169093A (ko) 2023-12-15
KR20230020548A (ko) 2023-02-10
TW202308679A (zh) 2023-03-01
JP7181442B1 (ja) 2022-11-30
BR112023019622A2 (pt) 2023-11-14

Similar Documents

Publication Publication Date Title
MX2023013099A (es) Preparacion que contiene un compuesto de peptido ciclico y metodo para su produccion.
MX2021005295A (es) Tolilos sustituidos como fungidas.
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
UA122966C2 (uk) Композиції з покращеним ефектом інгібування уреази, які містять триамід (тіо)фосфорної кислоти і додаткові сполуки, такі як аміни і барвники
CR20230496A (es) Compuestos heterocíclicos
SG11201908817WA (en) Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound
ZA201805185B (en) Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms
SG11201906688VA (en) Novel ester compounds, method for the production thereof and use thereof
MX2021004474A (es) Compuestos que contienen deuterio.
BR112022004398A2 (pt) Cristal de derivado de 1,3,5-triazina ou solvato do mesmo e método para produção do mesmo
MX2020006370A (es) Pirazolopiridina-diamidas, su uso como insecticida y procesos para prepararlas.
WO2019207257A8 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
ZA202301378B (en) Solid form of compound
MX386015B (es) Compuesto novedoso que se une específicamente a receptor de ácido alfa-amino-3-hidroxi-5-metil-4-isoxazol-propiónico (ampa).
WO2020003272A8 (en) An improved process for the preparation of venetoclax
PH12018501620A1 (en) Pest control composition and pest control method
BR112022008647A2 (pt) Composto de imidazolidinona, método de preparação do mesmo e uso do mesmo
BR112021026061A2 (pt) Método para o tratamento de uma composição que compreende vanilina natural
MX2022004265A (es) Compuesto de aldehido y metodo para producir el mismo y composicion de fragancia.
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
MX2021000226A (es) Nuevo proceso para la preparacion de diamidas antranilicas.
MX2021001953A (es) Composicion de politiol.
MX2018015342A (es) Emulsion, procedimiento para su preparacion y su uso.
MX2019003121A (es) Fosfato de alcohol alcoxilado no clorado para trabajo de metal.
EA200900480A1 (ru) Новые соединения индола, способ их получения и фармацевтические композиции, которые их содержат